<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">        <PMID Version="1">30046386</PMID>        <DateRevised>            <Year>2018</Year>            <Month>07</Month>            <Day>29</Day>        </DateRevised>        <Article PubModel="Electronic-eCollection">            <Journal>                <ISSN IssnType="Electronic">1949-2553</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>9</Volume>                    <Issue>53</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Jul</Month>                        <Day>10</Day>                    </PubDate>                </JournalIssue>                <Title>Oncotarget</Title>                <ISOAbbreviation>Oncotarget</ISOAbbreviation>            </Journal>            <ArticleTitle>The matrix protein Fibulin-3 promotes KISS1R induced triple negative breast cancer cell invasion.</ArticleTitle>            <Pagination>                <MedlinePgn>30034-30052</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.18632/oncotarget.25682</ELocationID>            <Abstract>                <AbstractText>Breast cancer is a leading cause of cancer mortality. In particular, triple negative breast cancer (TNBC) comprise a heterogeneous group of basal-like tumors lacking estrogen receptor (ERÎ±), progesterone receptor (PR) and HER2 (ErbB2). TNBC represents 15-20% of all breast cancers and occurs frequently in women under 50 years of age. Unfortunately, these patients lack targeted therapy, are typically high grade and metastatic at time of diagnosis. The mechanisms regulating metastasis remain poorly understood. We have previously shown that the kisspeptin receptor, KISS1R stimulates invasiveness of TNBC cells. In this report, we demonstrate that KISS1R signals via the secreted extracellular matrix protein, fibulin-3, to regulate TNBC invasion. We found that the fibulin-3 gene is amplified in TNBC primary tumors and that plasma fibulin-3 levels are elevated in TNBC patients compared to healthy subjects. In this study, we show that KISS1R activation increases fibulin-3 expression and secretion. We show that fibulin-3 regulates TNBC metastasis in a mouse experimental metastasis xenograft model and signals downstream of KISS1R to stimulate TNBC invasion, by activating matrix metalloproteinase 9 (MMP-9) and the MAPK pathway. These results identify fibulin-3 as a new downstream mediator of KISS1R signaling and as a potential biomarker for TNBC progression and metastasis, thus revealing KISS1R and fibulin-3 as novel drug targets in TNBC.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Noonan</LastName>                    <ForeName>Michelle M</ForeName>                    <Initials>MM</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Physiology and Pharmacology, The University of Western Ontario, London, ON, Canada.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Dragan</LastName>                    <ForeName>Magdalena</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Physiology and Pharmacology, The University of Western Ontario, London, ON, Canada.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Mehta</LastName>                    <ForeName>Michael M</ForeName>                    <Initials>MM</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Physiology and Pharmacology, The University of Western Ontario, London, ON, Canada.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Hess</LastName>                    <ForeName>David A</ForeName>                    <Initials>DA</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Physiology and Pharmacology, The University of Western Ontario, London, ON, Canada.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Krembil Centre for Stem Cell Biology, Molecular Medicine Research Group, Robarts Research Institute, London, ON, Canada.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Brackstone</LastName>                    <ForeName>Muriel</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Oncology, The University of Western Ontario, London, ON, Canada.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Lawson Health Research Institute, The University of Western Ontario, London, ON, Canada.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Division of Surgical Oncology, The University of Western Ontario, London, ON, Canada.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Tuck</LastName>                    <ForeName>Alan B</ForeName>                    <Initials>AB</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Oncology, The University of Western Ontario, London, ON, Canada.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Pathology, The University of Western Ontario, London, ON, Canada.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>The Pamela Greenaway-Kohlmeier Translational Breast Cancer Research Unit, London Regional Cancer Program, London, ON, Canada.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Viswakarma</LastName>                    <ForeName>Navin</ForeName>                    <Initials>N</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Surgery, Division of Surgical Oncology, University of Illinois at Chicago, Chicago, IL, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Rana</LastName>                    <ForeName>Ajay</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Surgery, Division of Surgical Oncology, University of Illinois at Chicago, Chicago, IL, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Babwah</LastName>                    <ForeName>Andy V</ForeName>                    <Initials>AV</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Pediatrics, Child Health Institute of NJ, Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Wondisford</LastName>                    <ForeName>Frederic E</ForeName>                    <Initials>FE</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medicine, Child Health Institute of NJ, Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Bhattacharya</LastName>                    <ForeName>Moshmi</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Physiology and Pharmacology, The University of Western Ontario, London, ON, Canada.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Oncology, The University of Western Ontario, London, ON, Canada.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Lawson Health Research Institute, The University of Western Ontario, London, ON, Canada.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Medicine, Child Health Institute of NJ, Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ, USA.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>07</Month>                <Day>10</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>Oncotarget</MedlineTA>            <NlmUniqueID>101532965</NlmUniqueID>            <ISSNLinking>1949-2553</ISSNLinking>        </MedlineJournalInfo>        <CommentsCorrectionsList>            <CommentsCorrections RefType="Cites">                <RefSource>Nat Rev Cancer. 2016 Apr;16(4):201-18</RefSource>                <PMID Version="1">27009393</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Int J Cancer. 2015 Mar 1;136(5):E359-86</RefSource>                <PMID Version="1">25220842</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4336-44</RefSource>                <PMID Version="1">17671114</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>PLoS One. 2014 Jan 13;9(1):e84958</RefSource>                <PMID Version="1">24454770</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Res. 2014 Oct 1;74(19):5435-5448</RefSource>                <PMID Version="1">25139440</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nat Rev Cancer. 2010 Feb;10(2):147-56</RefSource>                <PMID Version="1">20075923</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Cell Commun Signal. 2012 Jun;6(2):87-95</RefSource>                <PMID Version="1">22227894</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nat Med. 2013 Nov;19(11):1423-37</RefSource>                <PMID Version="1">24202395</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Proc Natl Acad Sci U S A. 2005 Feb 1;102(5):1761-6</RefSource>                <PMID Version="1">15665093</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Microenviron. 2014 Aug;7(1-2):71-8</RefSource>                <PMID Version="1">24858419</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Int J Cancer. 2008 May 1;122(9):2050-6</RefSource>                <PMID Version="1">18172859</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Target Oncol. 2014 Dec;9(4):349-57</RefSource>                <PMID Version="1">24233638</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nat Rev Cancer. 2007 Feb;7(2):139-47</RefSource>                <PMID Version="1">17218951</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncotarget. 2016 Jul 12;7(28):43518-43533</RefSource>                <PMID Version="1">27270657</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>N Engl J Med. 2010 Nov 11;363(20):1938-48</RefSource>                <PMID Version="1">21067385</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Lung Cancer. 2010 Aug;69(2):239-44</RefSource>                <PMID Version="1">19913326</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>N Engl J Med. 2003 Oct 23;349(17):1614-27</RefSource>                <PMID Version="1">14573733</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Mol Cancer. 2011 Sep 28;10:123</RefSource>                <PMID Version="1">21955618</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Asian Pac J Cancer Prev. 2015;16(4):1403-7</RefSource>                <PMID Version="1">25743806</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncol Rep. 2014 Jan;31(1):79-86</RefSource>                <PMID Version="1">24142183</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Endocrinology. 2012 Dec;153(12):5875-87</RefSource>                <PMID Version="1">23070548</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Endocrinol Metab. 2011 Aug;96(8):E1228-36</RefSource>                <PMID Version="1">21632807</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>PLoS One. 2013;8(2):e56174</RefSource>                <PMID Version="1">23405264</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Biol Chem. 2009 Dec;390(12):1293-302</RefSource>                <PMID Version="1">19804359</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nat Genet. 1999 Jun;22(2):199-202</RefSource>                <PMID Version="1">10369267</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncol Rep. 2016 Jun;35(6):3489-95</RefSource>                <PMID Version="1">27108677</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>BMC Cancer. 2014 Aug 23;14:609</RefSource>                <PMID Version="1">25151367</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Endocrinology. 2011 Apr;152(4):1616-26</RefSource>                <PMID Version="1">21285314</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Vis Exp. 2014 Jun 11;(88):null</RefSource>                <PMID Version="1">24961804</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Cell Mol Med. 2011 Mar;15(3):535-44</RefSource>                <PMID Version="1">20132413</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>PLoS One. 2012;7(11):e48237</RefSource>                <PMID Version="1">23144858</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncogene. 2017 Sep 14;36(37):5243-5251</RefSource>                <PMID Version="1">28504717</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Pharmacol Rev. 2010 Dec;62(4):565-78</RefSource>                <PMID Version="1">21079036</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Mol Cancer Res. 2009 Feb;7(2):189-98</RefSource>                <PMID Version="1">19208748</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Biol Chem. 2015 Feb 13;290(7):4383-97</RefSource>                <PMID Version="1">25548290</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Mod Pathol. 2014 Sep;27(9):1212-22</RefSource>                <PMID Version="1">24406864</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncotarget. 2015 Jun 10;6(16):14191-208</RefSource>                <PMID Version="1">25987128</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Biol Chem. 2001 Sep 14;276(37):34631-6</RefSource>                <PMID Version="1">11457843</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Eur J Gynaecol Oncol. 2016;37(1):80-5</RefSource>                <PMID Version="1">27048115</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Chemother Pharmacol. 2009 Mar;63(4):571-82</RefSource>                <PMID Version="1">19083000</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Neoplasma. 2011;58(5):441-8</RefSource>                <PMID Version="1">21744999</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Exp Metastasis. 2005;22(6):503-11</RefSource>                <PMID Version="1">16320113</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Matrix Biol. 1999 Oct;18(5):469-80</RefSource>                <PMID Version="1">10601734</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Cell Mol Med. 2009 Aug;13(8B):2236-52</RefSource>                <PMID Version="1">18681906</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Oncol Pharm Pract. 2012 Mar;18(1):68-75</RefSource>                <PMID Version="1">21422149</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>PLoS One. 2011;6(6):e21599</RefSource>                <PMID Version="1">21738726</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast Cancer. 2014 Jan;21(1):66-74</RefSource>                <PMID Version="1">22481575</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncotarget. 2017 Sep 15;8(45):79046-79060</RefSource>                <PMID Version="1">29108286</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Endocrinology. 2008 Aug;149(8):3926-32</RefSource>                <PMID Version="1">18450966</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Gynecol Oncol. 2010 Jun;117(3):417-22</RefSource>                <PMID Version="1">20378157</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Neuroendocrinology. 2013;97(2):193-202</RefSource>                <PMID Version="1">22377698</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Cell Sci. 2008 Feb 1;121(Pt 3):391-403</RefSource>                <PMID Version="1">18216334</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>N Engl J Med. 2012 Oct 11;367(15):1417-27</RefSource>                <PMID Version="1">23050525</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cell Death Dis. 2014 Apr 24;5:e1194</RefSource>                <PMID Version="1">24763051</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Pathol. 2010 Dec;222(4):367-79</RefSource>                <PMID Version="1">20927779</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>PLoS One. 2013 Nov 13;8(11):e78783</RefSource>                <PMID Version="1">24236050</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Mol Cancer Res. 2009 Jul;7(7):1064-77</RefSource>                <PMID Version="1">19609003</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Mol Cancer Res. 2009 Nov;7(11):1756-70</RefSource>                <PMID Version="1">19887559</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Onco Targets Ther. 2015 Jun 09;8:1387-98</RefSource>                <PMID Version="1">26089687</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Histol Histopathol. 2015 Jun;30(6):715-23</RefSource>                <PMID Version="1">25535062</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>EMBO Rep. 2003 Dec;4(12):1127-31</RefSource>                <PMID Version="1">14647206</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Sci Rep. 2017 Apr 19;7:46525</RefSource>                <PMID Version="1">28422142</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cell Signal. 2016 Mar;28(3):165-176</RefSource>                <PMID Version="1">26721186</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Mol Endocrinol. 2014 Jan;28(1):16-27</RefSource>                <PMID Version="1">24295737</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Zhongguo Fei Ai Za Zhi. 2015 Feb;18(2):92-7</RefSource>                <PMID Version="1">25676403</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Mol Endocrinol. 2009 Dec;23(12):2060-74</RefSource>                <PMID Version="1">19846537</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncotarget. 2017 Feb 21;8(8):13030-13038</RefSource>                <PMID Version="1">28103581</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>FASEB J. 2015 Feb;29(2):565-75</RefSource>                <PMID Version="1">25389134</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Genet Cytogenet. 2010 Dec;203(2):222-9</RefSource>                <PMID Version="1">21156237</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>PLoS One. 2010 Sep 23;5(9):e12964</RefSource>                <PMID Version="1">20886089</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Endocrinology. 2013 Jun;154(6):1999-2014</RefSource>                <PMID Version="1">23525242</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nature. 2001 May 31;411(6837):613-7</RefSource>                <PMID Version="1">11385580</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast J. 2011 Jul-Aug;17(4):377-82</RefSource>                <PMID Version="1">21615820</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cell Mol Life Sci. 2009 Jun;66(11-12):1890-902</RefSource>                <PMID Version="1">19189051</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>PLoS One. 2016 May 09;11(5):e0155087</RefSource>                <PMID Version="1">27158817</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Res. 2011 Oct 15;71(20):6535-46</RefSource>                <PMID Version="1">21852382</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Cancer. 2013 Sep 26;4(8):653-61</RefSource>                <PMID Version="1">24155777</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Asian Pac J Cancer Prev. 2011;12(8):2139-43</RefSource>                <PMID Version="1">22292666</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Neuroreport. 2013 Jul 10;24(10):504-8</RefSource>                <PMID Version="1">23660683</PMID>            </CommentsCorrections>        </CommentsCorrectionsList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">fibulin-3</Keyword>            <Keyword MajorTopicYN="N">invasion</Keyword>            <Keyword MajorTopicYN="N">kisspeptin receptor</Keyword>            <Keyword MajorTopicYN="N">metastasis</Keyword>            <Keyword MajorTopicYN="N">triple-negative breast cancer</Keyword>        </KeywordList>        <CoiStatement>CONFLICTS OF INTEREST The authors have no conflicts to disclose.</CoiStatement>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2017</Year>                <Month>09</Month>                <Day>22</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>06</Month>                <Day>13</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>7</Month>                <Day>27</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>7</Month>                <Day>27</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>7</Month>                <Day>27</Day>                <Hour>6</Hour>                <Minute>1</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>epublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30046386</ArticleId>            <ArticleId IdType="doi">10.18632/oncotarget.25682</ArticleId>            <ArticleId IdType="pii">25682</ArticleId>            <ArticleId IdType="pmc">PMC6059025</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>